Evidence map›Paper›PMID 30684034›Full record

ReviewWorld journal of urology2019

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Jeffrey J Leow, Jens Bedke, Karim Chamie, Justin W Collins, Siamak Daneshmand, Petros Grivas, Axel Heidenreich, Edward M Messing, Trevor J Royce, Alexander I Sankin and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Novel dihydroartemisinin derivative Mito-DHABMC pharmacology & toxicology · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 7 countries.

Jeffrey J LeowDepartment of Urology, Tan Tock Seng Hospital, Singapore, Singapore.
Jens BedkeDepartment of Urology, University of Tübingen, Tübingen, Germany.
Karim ChamieDepartment of Urology and Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Justin W CollinsDepartment of Molecular Medicine and Surgery (MMK), Karolinska Institutet, Solna, Sweden.
Siamak DaneshmandUSC Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Petros GrivasDivision of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Axel HeidenreichDepartment of Urology, University Hospital of Cologne, Cologne, Germany.
Edward M MessingDepartment of Urology, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Trevor J RoyceDepartment of Radiation Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Alexander I SankinDepartment of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Mark P SchoenbergDepartment of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
William U ShipleyGenitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Arnauld VillersDepartment of Urology, University of Lille Nord de France, Lille, France.
Jason A EfstathiouGenitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. jefstathiou@partners.org.
Joaquim BellmuntPSMAR-IMIM Hospital del Mar Medical Research Institute, Barcelona, Spain. jbellmunt@imim.es.
Arnulf StenzlDepartment of Urology, University of Tübingen, Tübingen, Germany. arnulf.stenzl@med.uni-tuebingen.de.
University of Tübingen · DEAlbert Einstein College of Medicine · USHarvard University · USHospital del Mar Research Institute · ESMassachusetts General Hospital · USMontefiore Medical Center · USORSI Academy · BETan Tock Seng Hospital · SGUniversité Lille Nord de France · FRUniversity Hospital Cologne · DEUniversity of California, Los Angeles · USUniversity of North Carolina at Chapel Hill · USUniversity of Rochester Medical Center · USUniversity of Southern California · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo provide a comprehensive overview and update of the Joint Société Internationale d'Urologie-International Consultation on Urological Diseases (SIU-ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC).

methodsContemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine.

resultsRadical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3-4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation.

conclusionA multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.

Indexed as

Combined Modality TherapyConsensusCystectomyHumansNeoplasm InvasivenessSocieties, MedicalUrinary Bladder NeoplasmsAdjuvant chemotherapyBladder-sparingChemoradiationEnhanced recovery after surgeryMuscle-invasive bladder cancerNeoadjuvant chemotherapyRadical cystectomyTransurethral resection of bladder tumorTrimodalUrothelial carcinoma of bladderVariant histology

Identifiers

PMID30684034
OpenAlexW2912530549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.